Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

H. M. Heshmati, Sundeep Khosla, S. P. Robins, M. W. O'Fallon, L. J. Melton, L. Riggs

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Although median levels of bone turnover are increased in postmenopausal women, it is unclear whether the low circulating levels of endogenous estrogen exert a regulatory role on these levels. This issue was evaluated by assessing the effect of a blockade of estrogen synthesis on bone turnover markers in 42 normal women (mean age ± SD, 69 ± 5 years) randomly assigned to groups receiving the potent aromatase inhibitor letrozole or placebo for 6 months. Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0.0001). This treatment did not affect bone formation markers but, as compared with the placebo group, increased bone resorption markers (urine 24-h pyridinoline [PYD] by 13.3% [p <0.05] and 24-h urine deoxypyridinoline [DPD] by 14.2% [p < 0.05] and decreased serum parathyroid hormone (PTH) by 22% (p = 0.002). These data indicate that in late postmenopausal women even the low serum estrogen levels present exert a restraining effect on bone turnover and support the concept that variations in these low levels may contribute to differences in their rate of bone loss.

Original languageEnglish (US)
Pages (from-to)172-178
Number of pages7
JournalJournal of Bone and Mineral Research
Volume17
Issue number1
StatePublished - 2002

Fingerprint

letrozole
Bone Remodeling
Bone Resorption
Estrogens
Serum
Placebos
Urine
Aromatase Inhibitors
Estrone
Parathyroid Hormone
Osteogenesis
Estradiol
Bone and Bones
Therapeutics

Keywords

  • Bone turnover
  • Estrogen
  • Postmenopausal bone loss

ASJC Scopus subject areas

  • Surgery

Cite this

Heshmati, H. M., Khosla, S., Robins, S. P., O'Fallon, M. W., Melton, L. J., & Riggs, L. (2002). Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. Journal of Bone and Mineral Research, 17(1), 172-178.

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. / Heshmati, H. M.; Khosla, Sundeep; Robins, S. P.; O'Fallon, M. W.; Melton, L. J.; Riggs, L.

In: Journal of Bone and Mineral Research, Vol. 17, No. 1, 2002, p. 172-178.

Research output: Contribution to journalArticle

Heshmati, HM, Khosla, S, Robins, SP, O'Fallon, MW, Melton, LJ & Riggs, L 2002, 'Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women', Journal of Bone and Mineral Research, vol. 17, no. 1, pp. 172-178.
Heshmati, H. M. ; Khosla, Sundeep ; Robins, S. P. ; O'Fallon, M. W. ; Melton, L. J. ; Riggs, L. / Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. In: Journal of Bone and Mineral Research. 2002 ; Vol. 17, No. 1. pp. 172-178.
@article{220d6aae2ade419689feb29f55b94f17,
title = "Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women",
abstract = "Although median levels of bone turnover are increased in postmenopausal women, it is unclear whether the low circulating levels of endogenous estrogen exert a regulatory role on these levels. This issue was evaluated by assessing the effect of a blockade of estrogen synthesis on bone turnover markers in 42 normal women (mean age ± SD, 69 ± 5 years) randomly assigned to groups receiving the potent aromatase inhibitor letrozole or placebo for 6 months. Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0.0001). This treatment did not affect bone formation markers but, as compared with the placebo group, increased bone resorption markers (urine 24-h pyridinoline [PYD] by 13.3{\%} [p <0.05] and 24-h urine deoxypyridinoline [DPD] by 14.2{\%} [p < 0.05] and decreased serum parathyroid hormone (PTH) by 22{\%} (p = 0.002). These data indicate that in late postmenopausal women even the low serum estrogen levels present exert a restraining effect on bone turnover and support the concept that variations in these low levels may contribute to differences in their rate of bone loss.",
keywords = "Bone turnover, Estrogen, Postmenopausal bone loss",
author = "Heshmati, {H. M.} and Sundeep Khosla and Robins, {S. P.} and O'Fallon, {M. W.} and Melton, {L. J.} and L. Riggs",
year = "2002",
language = "English (US)",
volume = "17",
pages = "172--178",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

AU - Heshmati, H. M.

AU - Khosla, Sundeep

AU - Robins, S. P.

AU - O'Fallon, M. W.

AU - Melton, L. J.

AU - Riggs, L.

PY - 2002

Y1 - 2002

N2 - Although median levels of bone turnover are increased in postmenopausal women, it is unclear whether the low circulating levels of endogenous estrogen exert a regulatory role on these levels. This issue was evaluated by assessing the effect of a blockade of estrogen synthesis on bone turnover markers in 42 normal women (mean age ± SD, 69 ± 5 years) randomly assigned to groups receiving the potent aromatase inhibitor letrozole or placebo for 6 months. Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0.0001). This treatment did not affect bone formation markers but, as compared with the placebo group, increased bone resorption markers (urine 24-h pyridinoline [PYD] by 13.3% [p <0.05] and 24-h urine deoxypyridinoline [DPD] by 14.2% [p < 0.05] and decreased serum parathyroid hormone (PTH) by 22% (p = 0.002). These data indicate that in late postmenopausal women even the low serum estrogen levels present exert a restraining effect on bone turnover and support the concept that variations in these low levels may contribute to differences in their rate of bone loss.

AB - Although median levels of bone turnover are increased in postmenopausal women, it is unclear whether the low circulating levels of endogenous estrogen exert a regulatory role on these levels. This issue was evaluated by assessing the effect of a blockade of estrogen synthesis on bone turnover markers in 42 normal women (mean age ± SD, 69 ± 5 years) randomly assigned to groups receiving the potent aromatase inhibitor letrozole or placebo for 6 months. Letrozole treatment reduced serum estrone (E1) and estradiol (E2) to near undetectable levels (p < 0.0001). This treatment did not affect bone formation markers but, as compared with the placebo group, increased bone resorption markers (urine 24-h pyridinoline [PYD] by 13.3% [p <0.05] and 24-h urine deoxypyridinoline [DPD] by 14.2% [p < 0.05] and decreased serum parathyroid hormone (PTH) by 22% (p = 0.002). These data indicate that in late postmenopausal women even the low serum estrogen levels present exert a restraining effect on bone turnover and support the concept that variations in these low levels may contribute to differences in their rate of bone loss.

KW - Bone turnover

KW - Estrogen

KW - Postmenopausal bone loss

UR - http://www.scopus.com/inward/record.url?scp=0036133521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036133521&partnerID=8YFLogxK

M3 - Article

C2 - 11771665

AN - SCOPUS:0036133521

VL - 17

SP - 172

EP - 178

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 1

ER -